Clinical Evaluation of the VIPUN Balloon Catheter 0.1
- Conditions
- Gastric EmptyingHealthyMotility Disorder
- Interventions
- Device: VIPUN Balloon Catheter 0.1 deflatedDrug: PlaceboDevice: VIPUN Balloon Catheter 0.1 inflated
- Registration Number
- NCT03239821
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Brief Summary
The primary aim of this investigation is to assess the safety, feasibility and performance of the VIPUN Balloon Catheter 0.1 in the assessment of gastric motility. The investigation will also assess whether the inflation of the VIPUN Balloon Catheter can stimulate gastric motility and emptying. Furthermore, this investigation will examine whether gastric motility and emptying as measured in this study are correlated.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 22
- Signed Informed Consent
- Aged between and including 18 and 65 years
- BMI between and including 18 and 25
- Understand and able to read Dutch
- In good health on the basis of medical history
- Able to return home without driving a vehicle on visit days 1-4
- Will not operate machines on the same day of treatment (visits 1-4)
- Females subjects of childbearing potential are willing to use adequate contraception
- Refrains from herbal, vitamin and other dietary supplements on the day of the visits
Exclusion criteria related to possible influence on end-points:
- Dyspeptic symptoms (assessed with PAGI-SYM questionnaire)
- Using any medication that might affect gastric function or visceral sensitivity
- Known / suspected current use of illicit drugs
- Known psychiatric or neurological illness
- Any gastrointestinal surgery that could influence normal gastric function in the opinion of the investigator
Exclusion criteria related to positioning of the catheter:
- History of heart or vascular diseases like irregular heartbeats, angina or heart attack
- Nasopharyngeal, upper GI or esophageal surgery in the last 30 days
- Suspected basal skull fracture or severe maxillofacial trauma
- History of thermal or chemical injury to upper respiratory tract or esophagus
- Current esophageal or nasopharyngeal obstruction
- Known coagulopathy
- Known esophageal varices
Exclusion criteria related to codeine administration:
- History of opioid dependency
- Known severely decreased kidney or liver function
- Pregnant or breastfeeding women (pregnancy test will be performed on females with childbearing potential)
- Known severe lung disease (e.g. asthma or emphysema)
- Have known side-effects/allergic reactions when taking codeine/morphine
- Known diabetic, fructose intolerance or malabsorption of glucose or galactose or sucrose-isomalase insufficiency.
Exclusion criteria related to Sirupus simplex administration:
• Known diabetic (saccharose), intolerance to or malabsorption of propylene glycol and methyl- and propylparahydroxybenzoate
Exclusion criteria related to nutrients (Fortimel):
• Have a known allergy or intolerance to cow milk, soy, saccharose or any other ingredient of Fortimel Energy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Codeine - delfated balloon VIPUN Balloon Catheter 0.1 deflated - Placebo - deflated balloon VIPUN Balloon Catheter 0.1 deflated - Placebo - deflated balloon Placebo - Placebo - inflated balloon Placebo - Placebo - inflated balloon VIPUN Balloon Catheter 0.1 inflated - Codeine - delfated balloon Codeine Phosphate - Codeine - inflated balloon VIPUN Balloon Catheter 0.1 inflated - Codeine - inflated balloon Codeine Phosphate -
- Primary Outcome Measures
Name Time Method Safety: Incidence, frequency, severity, seriousness and relatedness of AEs during the 8 hour visit. 8 hours Incidence, frequency, severity, seriousness and relatedness of AEs
Feasibility: Success rate in completing the procedure (placement and removal VIPUN Balloon Catheter) during the 8 hour visit. 8 hours Success rate in completing the procedure (placement and removal VIPUN Balloon Catheter)
Performance: Motility index (MI) decrease after codeine treatment vs. placebo treatment (inflated balloon) during the 8 hour visit. 8 hours Motility index (MI) decrease after codeine treatment vs. placebo treatment (inflated balloon)
- Secondary Outcome Measures
Name Time Method Change in gastric emptying: placebo vs. codeine and deflated vs. inflated balloon 8 hours To explore whether the VIPUN Balloon Catheter 0.1 can influence gastric motility and/or emptying.
Correlation motility index change and gastric emptying time change: placebo vs. codeine (inflated balloon) 8 hours To explore whether there is a correlation between gastric motility and emptying.
Trial Locations
- Locations (1)
UZ Leuven Gasthuisberg
🇧🇪Leuven, Belgium